Aeolus Announces First Quarter Fiscal Year 2014 Financial Results
February 14, 2014 17:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 14, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New Formulation
February 13, 2014 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 13, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
90% reduction in manufacturing cost of drug substance achieved;...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy Studies
February 10, 2014 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 10, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Three papers published in Health Physics, Volume 106, Number 1 (January 2014)
...
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA
January 23, 2014 10:52 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jan 23, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Fiscal Year 2013 Financial Results
December 23, 2013 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Dec 23, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Files Application for New Patent on AEOL 10150
December 05, 2013 11:14 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Dec 5, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Filing covers synthesis, formulation and pharmaceutical composition
...
Aeolus' AEOl 10150 Significantly Improves Survival and Protects Lungs in Mice Exposed to Lethal Radiation
October 29, 2013 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Oct 29, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Optimal dose of AEOL 10150 improved survival by four times over untreated...
BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation Syndrome
September 17, 2013 13:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Sep 17, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
BARDA exercise options valued at $6.0 million effective September 16, 2013...
Aeolus' AEOL 10150 Subject of $4.3 Million US Government Award for Protection Against Nerve Agents; Data Shows Drug Significantly Improves Survival in Animals Following Exposure to Pilocarpine, a Nerve Agent Surrogate for Soman and Sarin Gas
September 11, 2013 12:20 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Sep 11, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
National Institutes of Health - National Institute of Neurological...
Aeolus Announces Third Quarter Fiscal Year 2013 Financial Results
August 14, 2013 16:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 14, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...